



# Management of the Suprapontine Neurogenic Lower Urinary Tract Dysfunction

8

Gaetano De Rienzo, Gianfranco Lamberti, Luisa De Palma, Donatella Giraudò, Elena Bertolucci, Giuseppina Gibertini, Caterina Grusso, and Roberta Robol

## 8.1 Pharmacotherapy

In the case of suprapontine lesions, the most common bladder dysfunction is neurogenic detrusor overactivity. Antimuscarinics can be considered the mainstay of treatment, while other therapies like cannabinoids look promising. Intravesical injection of botulinum toxin can be considered the main second-line treatment in case of failure of antimuscarinics. Conservative treatments should be associated with drugs. Cognitive effects of therapy shall be bared in mind for all the therapies with systemic absorption.

**per il full-text contatta gli autori  
giraudò.donatella@hsr.it  
gianfrancolamberti@icloud.com**

G. De Rienzo

Urology and Andrology Unit, University of Bari, Bari, Italy

G. Lamberti (✉)

Neurorehabilitation Unit and Pelvic Floor Dysfunction Rehabilitation Center, SS Trinità Hospital, Cuneo, Italy

L. De Palma

UOC MFR and Unipolar Spinal Unit, Polyclinic Consortium Hospital of Bari, Bari, Italy

D. Giraudò

Urology Department, San Raffaele Turro Hospital, Milan, Italy

e-mail: [giraudò.donatella@hsr.it](mailto:giraudò.donatella@hsr.it)

E. Bertolucci · G. Gibertini

Neuro-Urology Unit, CTO - Spinal Unit, Città della Salute e della Scienza di Torino, Turin, Italy

e-mail: [ggibertini@cittadellasalute.to.it](mailto:ggibertini@cittadellasalute.to.it)

C. Grusso

University of Rome Tor Vergata, Rome, Italy

R. Robol

ASST dei Sette Laghi, Hospital “Del Ponte”, Varese, Italy

© Springer Nature Switzerland AG 2020

G. Lamberti et al. (eds.), *Suprapontine Lesions and Neurogenic Pelvic Dysfunctions*, Urodynamics, Neurourology and Pelvic Floor Dysfunctions, [https://doi.org/10.1007/978-3-030-29775-6\\_8](https://doi.org/10.1007/978-3-030-29775-6_8)